What is peptide receptor radioligand therapy?
- Peptide receptor radioligand therapy takes advantage of the presence of somatostatin receptors on NETs to deliver radiopharmaceuticals directly to these tumors.
- NETs that show significant tracer uptake on somatostatin receptor–based functional imaging (68-Ga DOTATATE or In-111 pentetreotide) can subsequently be treated with one of several labeled analogues, such as 177-Lu DOTATATE, 90-Y edotreotide, or 90-Y DOTA tyr3-octreotide.
- Promising results in terms of symptom control have been reported in clinical trials.
